Authors perspective and future directions Current evidence supports SGLT2 inhibitors as a core component of contemporary heart failure management because of their consistent reductions in HF hospitalization and cardiovascular death across a broad range of patient populations [8,9,10,11,12,13, 45, 49]
Preclinical Observations Findings observed in murine studies include: Endurance capacity: Increased treadmill running time and distance Mitochondrial function: Enhanced respiration and ATP production in muscle Cardiac metabolism: Improved fatty acid utilization in models of heart failure Renal function: Reduced mitochondrial dysfunction and inflammation in aging kidney models Metabolic profile: Improved glucose handling in metabolic syndrome models These results are limited to animal models using intraperitoneal injection
Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
How are you managing multi-state licensing and credentialing as you expand
Stanford shares key strategies for maximizing the benefits of GLP-1 medications and ensuring long-term success: Adopt a holistic approach: GLP-1 medications should be part of a comprehensive health plan
